Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EWTX Edgewise Therapeutics	$13.58 +0.3%	$14.22	$10.60 ▼ $38.12	$1.44B	0.25	1.18 million shs	17,919 shs
HUMA Humacyte	$2.38 +1.9%	$2.35	$1.15 ▼ $9.79	$368.41M	1.89	3.77 million shs	399,403 shs
TVTX Travere Therapeutics	$16.12 +0.1%	$15.87	$7.93 ▼ $25.29	$1.43B	0.72	1.61 million shs	95,497 shs
VERA Vera Therapeutics	$23.24 +0.8%	$22.78	$18.53 ▼ $51.61	$1.49B	1.19	1.29 million shs	122,385 shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EWTX Edgewise Therapeutics	0.00%	-2.17%	-5.31%	+1.80%	-36.61%
HUMA Humacyte	0.00%	+0.87%	+0.87%	+60.69%	-69.14%
TVTX Travere Therapeutics	0.00%	-2.19%	+12.58%	+6.62%	+64.39%
VERA Vera Therapeutics	0.00%	-3.23%	+10.50%	+9.19%	-33.48%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EWTX Edgewise Therapeutics	1.471 of 5 stars	3.4	0.0	1.8	2.5	0.0
HUMA Humacyte	1.5191 of 5 stars	3.5	1.0	1.1	0.8	0.6
TVTX Travere Therapeutics	3.6834 of 5 stars	4.4	5.0	2.2	0.8	0.6
VERA Vera Therapeutics	4.0633 of 5 stars	4.6	5.0	1.9	4.2	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EWTX Edgewise Therapeutics	2.80	Moderate Buy	$40.00	194.55% Upside
HUMA Humacyte	3.00	Buy	$11.71	393.23% Upside
TVTX Travere Therapeutics	2.87	Moderate Buy	$32.14	99.39% Upside
VERA Vera Therapeutics	3.10	Buy	$65.00	179.75% Upside

Current Analyst Ratings Breakdown

Latest HUMA, VERA, TVTX, and EWTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/9/2025	HUMA Humacyte	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
7/1/2025	TVTX Travere Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$30.00
6/30/2025	EWTX Edgewise Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$42.00
6/11/2025	TVTX Travere Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$30.00
6/11/2025	TVTX Travere Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$35.00 ➝ $32.00
6/9/2025	HUMA Humacyte	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
6/5/2025	EWTX Edgewise Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$48.00
6/3/2025	VERA Vera Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
6/3/2025	VERA Vera Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
6/2/2025	VERA Vera Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Sector Outperform ➝ Sector Outperform	$55.00 ➝ $65.00
6/2/2025	VERA Vera Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $85.00

(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	$4.84 per share	N/A
HUMA Humacyte	$1.57M	234.66	N/A	N/A	($0.41) per share	-5.79
TVTX Travere Therapeutics	$233.18M	6.14	N/A	N/A	$0.76 per share	21.21
VERA Vera Therapeutics	N/A	N/A	N/A	N/A	$9.08 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EWTX Edgewise Therapeutics	-$133.81M	-$1.55	N/A	N/A	N/A	N/A	-30.95%	-29.45%	8/6/2025 (Estimated)
HUMA Humacyte	-$148.70M	-$0.69	N/A	N/A	N/A	N/A	N/A	-73.59%	8/12/2025 (Estimated)
TVTX Travere Therapeutics	-$321.55M	-$2.81	N/A	N/A	N/A	-82.88%	-1,179.73%	-41.10%	7/30/2025 (Estimated)
VERA Vera Therapeutics	-$152.15M	-$3.00	N/A	N/A	N/A	N/A	-40.59%	-34.54%	8/6/2025 (Estimated)

Latest HUMA, VERA, TVTX, and EWTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	EWTX Edgewise Therapeutics	-$0.42	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	VERA Vera Therapeutics	-$0.82	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	HUMA Humacyte	-$0.15	N/A	N/A	N/A	$0.94 million	N/A
8/7/2025	Q2 2025	TVTX Travere Therapeutics	-$0.26	N/A	N/A	N/A	N/A	N/A
5/13/2025	Q1 2025	HUMA Humacyte	-$0.19	-$0.10	+$0.09	$0.28	$0.46 million	$0.52 million
5/8/2025	Q1 2025	EWTX Edgewise Therapeutics	-$0.45	-$0.43	+$0.02	-$0.43	N/A	N/A
5/8/2025	Q1 2025	VERA Vera Therapeutics	-$0.75	-$0.81	-$0.06	-$0.81	N/A	N/A
5/1/2025	Q1 2025	TVTX Travere Therapeutics	-$0.55	-$0.47	+$0.08	-$0.47	$77.44 million	$81.73 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	N/A
HUMA Humacyte	N/A	N/A	N/A	N/A	N/A
TVTX Travere Therapeutics	N/A	N/A	N/A	N/A	N/A
VERA Vera Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EWTX Edgewise Therapeutics	N/A	20.99	20.99
HUMA Humacyte	0.36	3.68	3.28
TVTX Travere Therapeutics	9.46	2.05	2.03
VERA Vera Therapeutics	0.10	27.68	27.68

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EWTX Edgewise Therapeutics	N/A
HUMA Humacyte	44.71%
TVTX Travere Therapeutics	N/A
VERA Vera Therapeutics	99.21%

Insider Ownership

Company	Insider Ownership
EWTX Edgewise Therapeutics	23.20%
HUMA Humacyte	5.10%
TVTX Travere Therapeutics	4.06%
VERA Vera Therapeutics	16.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EWTX Edgewise Therapeutics	60	105.20 million	80.79 million	Optionable
HUMA Humacyte	150	155.12 million	147.21 million	Optionable
TVTX Travere Therapeutics	460	88.81 million	85.20 million	Optionable
VERA Vera Therapeutics	40	63.77 million	53.38 million	Optionable

HUMA, VERA, TVTX, and EWTX Headlines

Recent News About These Companies

Vera Therapeutics, Inc. (NASDAQ:VERA) Stake Decreased by Jennison Associates LLC

5 hours ago | marketbeat.com

Vera Therapeutics, Inc. (NASDAQ:VERA) Receives $65.00 Consensus PT from Analysts

July 18 at 2:37 AM | americanbankingnews.com

Startup targets orphan kidney disease with former Merck drug

July 17, 2025 | medcitynews.comM

Reviewing Celcuity (NASDAQ:CELC) and Vera Therapeutics (NASDAQ:VERA)

July 16, 2025 | americanbankingnews.com

Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Consensus Recommendation of "Buy" from Brokerages

July 15, 2025 | marketbeat.com

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 10, 2025 | globenewswire.com

Vera Therapeutics Reports Positive Phase 3 ORIGIN Trial Results for Atacicept in IgA Nephropathy

July 6, 2025 | msn.com

Vera Therapeutics Inc Class A Sustainability - Morningstar

July 5, 2025 | morningstar.comM

Vera Therapeutics director Enright buys shares worth $5.2m

June 27, 2025 | investing.com

Vor Bio Reinvents Itself as an Autoimmune Biotech With In-Licensed Phase 3 Asset and $175M in Funding

June 27, 2025 | msn.com

Vera Therapeutics (NASDAQ:VERA) Shares Gap Up Following Insider Buying Activity

June 26, 2025 | marketbeat.com

Insider Buying: Vera Therapeutics, Inc. (NASDAQ:VERA) Director Acquires 40,607 Shares of Stock

June 26, 2025 | insidertrades.com

Vera Therapeutics, Inc. (NASDAQ:VERA) Director Patrick G. Enright Purchases 40,607 Shares

June 25, 2025 | marketbeat.com

Vera Therapeutics, Inc. (NASDAQ:VERA) Director Patrick G. Enright Acquires 209,393 Shares

June 25, 2025 | marketbeat.com

Polycythemia Vera Market Set for Strong Growth Across Key Markets, Backed by Emerging Treatments and Epidemiological Trends | DelveInsight

June 24, 2025 | theglobeandmail.com

BAFF- and APRIL-targeted Therapies Market Sees Surge in Activity Amid Rising Autoimmune Disease Burden | DelveInsight

June 24, 2025 | finance.yahoo.com

J.P. Morgan Reaffirms Their Buy Rating on Vera Therapeutics (VERA)

June 19, 2025 | theglobeandmail.com

Analysts Can't Get Enough of These Little-Known Biopharma Stocks (VERA)

...

June 12, 2025 | marketbeat.com

Vera Therapeutics Inc.

June 10, 2025 | barrons.com

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 9, 2025 | globenewswire.com

Otsuka, Vera stake their claims to IgAN treatment

June 9, 2025 | pharmaphorum.comP

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
Top 3 Bank Stocks to Watch as Fed Rate Cuts Loom
By Chris Markoch | June 25, 2025
View Top 3 Bank Stocks to Watch as Fed Rate Cuts Loom
Buffett's $2B+ Bet With Big Long-Term Potential Just Got Upgraded
By Leo Miller | July 10, 2025
View Buffett's $2B+ Bet With Big Long-Term Potential Just Got Upgraded
5 Small Cap Stocks With Explosive Upside Potential
By Ryan Hasson | June 23, 2025
View 5 Small Cap Stocks With Explosive Upside Potential
3 Retail Stocks to Watch as Back-to-School Spending Ramps Up
By Chris Markoch | July 14, 2025
View 3 Retail Stocks to Watch as Back-to-School Spending Ramps Up

HUMA, VERA, TVTX, and EWTX Company Descriptions

Edgewise Therapeutics NASDAQ:EWTX

$13.58 +0.04 (+0.30%)

As of 10:35 AM Eastern

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Humacyte NASDAQ:HUMA

$2.38 +0.05 (+1.93%)

As of 10:35 AM Eastern

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

Travere Therapeutics NASDAQ:TVTX

$16.12 +0.01 (+0.07%)

As of 10:36 AM Eastern

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Vera Therapeutics NASDAQ:VERA

$23.24 +0.19 (+0.80%)

As of 10:36 AM Eastern

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time